journal article·2019-12-04Open access

Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells

Leila Faramarzi, Mehdi Dadashpour, Hadi Sadeghzadeh, Majid Mahdavi, Nosratollah Zarghami

Abstract

Metformin (MET) has received considerable attention in recent years for its anticancer potential activities. However, short half-life and weak bioavailability of MET limited its use as a chemotherapeutic agent. The present study is intended to evaluate the efficiency of PLGA-PEG as a nano-carrier for MET to increase anticancer effects on SKOV3 ovarian carcinoma cells. MET-loaded PLGA-PEG nanoparticles (NPs) were characterized through Dynamic Light Scattering (DLS), Fourier-transform infrared spectroscopy (FTIR) and field emission scanning electron microscopy (FE-SEM). Anti-proliferative and apoptotic effects of nanoformulated MET were evaluated using MTT and flow-cytometric assays, respectively. Also, real-time polymerase chain reaction (Real-Time PCR) was used to determine the gene expression levels of apoptotic genes, p53 and hTERT. Evaluation of cytotoxicity showed that MET-NPs had more cytotoxicity than free MET in a time-and dose-dependent manner. The nuclei fragmentation and the percentage of apoptotic cells induced by MET-NPs were significantly higher than free MET. Also, it was found that MET-NPs triggered more cell cycle arrest at sub-G1 checkpoint than free MET. Compared to MET treated cells, the mRNA expression levels of apoptotic genes, as well as p53 and hTERT were significantly altered in MET-NPs treated cells. In conclusion, it is supposed that nano-encapsulation of MET into polymeric PLGA-PEG NPs may be a convenient drug delivery system to enhance its anticancer effects for ovarian cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer-related Molecular Pathways · Metabolism, Diabetes, and Cancer · Cell death mechanisms and regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biology, Faculty of Natural Sciences, University of Tabriz

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Hematology and Oncology Research Center, Tabriz University of Medical Sciences

Department of Tissue Engineering, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences

References (50)

Show source-provided references
1. 10.3322/caac.2139210.3322/caac.21392 ↗
2. De Souza C. Effect of germline polymorphisms on somatic mutations in High Grade Serous ovarian cancer. Poster session presented at: The University of New Mexico. Shared knowledge Conference; 2017 November 11;. Albuquerque New Mexico.
3. Maasomi ZJ, Pilehvar-Soltanahmadi Y, Dadashpour M, et al. Synergistic anticancer effects of silibinin and chrysin in T47D breast cancer cells. Asian Pac J Cancer Prev. 2017;18:1283.
4. 10.1055/a-0631-804610.1055/a-0631-8046 ↗
5. 10.1080/21691401.2017.140811610.1080/21691401.2017.1408116 ↗
6. 10.4161/cc.8.13.881410.4161/cc.8.13.8814 ↗
7. 10.1007/s11095-018-2404-710.1007/s11095-018-2404-7 ↗
8. 10.1002/ptr.590810.1002/ptr.5908 ↗
9. 10.1016/j.jddst.2017.09.01310.1016/j.jddst.2017.09.013 ↗
10. Jafari-Gharabaghlou D, Pilehvar-Soltanahmadi Y, Dadashpour M, et al. Combination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells. Iranian J Basic Med Sci. 2018;21:1167.
11. Rasouli S, Zarghami N. Synergistic growth inhibitory effects of chrysin and metformin combination on breast cancer cells through hTERT and cyclin D1 suppression. Asian Pac J Cancer Prev. 2018;19:977–982.
12. 10.1208/s12249-016-0505-310.1208/s12249-016-0505-3 ↗
13. 10.1080/21691401.2017.140811610.1080/21691401.2017.1408116 ↗
14. 10.3109/21691401.2015.102963310.3109/21691401.2015.1029633 ↗
15. 10.7314/APJCP.2015.16.18.825910.7314/APJCP.2015.16.18.8259 ↗
16. 10.1080/21691401.2017.134592510.1080/21691401.2017.1345925 ↗
17. 10.1016/j.yexcr.2017.05.01510.1016/j.yexcr.2017.05.015 ↗
18. 10.1016/j.biopha.2018.06.03710.1016/j.biopha.2018.06.037 ↗
19. Amirsaadat S, Pilehvar-Soltanahmadi Y, Zarghami F, et al. Silibinin-loaded magnetic nanoparticles inhibit hTERT gene expression and proliferation of lung cancer cells. Artificial Cells, Nanomed Biotechnol. 2013 2017;45:1649–1656.
20. 10.1016/j.msec.2018.07.05310.1016/j.msec.2018.07.053 ↗
21. 10.3390/ijms1910285010.3390/ijms19102850 ↗
22. 10.1593/neo.1114810.1593/neo.11148 ↗
23. Hart PC Sheikh S Lengyel E et al. Metformin inhibits TGFβ-induced stromal ECM remodeling to impede invasion in ovarian cancer. Paper presented at the 2017 AACR Annual Meeting; 2017 April 1–5; Chicago USA.
24. 10.1016/j.ygyno.2017.05.01910.1016/j.ygyno.2017.05.019 ↗
25. 10.2174/187152061666616081512453710.2174/1871520616666160815124537 ↗
26. Anganeh MT, Mirakabad FST, Izadi M, et al. The comparison between effects of free curcumin and curcumin loaded PLGA-PEG on telomerase and TRF1 expressions in calu-6 lung cancer cell line. Int J Biosci. 2014;4:134–145.
27. 10.7314/APJCP.2015.16.9.375310.7314/APJCP.2015.16.9.3753 ↗
28. 10.3389/fphar.2018.0126010.3389/fphar.2018.01260 ↗
29. 10.3109/21691401.2015.112961510.3109/21691401.2015.1129615 ↗
30. Amirsaadat S, Pilehvar-Soltanahmadi Y, Zarghami F, et al. The effects of nanoencapsulated curcumin-Fe3O4 on proliferation and hTERT gene expression in lung cancer cells. Acamc. 2017;17:1363–1373.
31. 10.17795/ijcp-419010.17795/ijcp-4190 ↗
32. 10.1080/21691401.2016.121685410.1080/21691401.2016.1216854 ↗
33. 10.1080/01635581.2017.136793210.1080/01635581.2017.1367932 ↗
34. 10.3109/1061186X.2013.83746910.3109/1061186X.2013.837469 ↗
35. 10.3109/10837450.2011.60478310.3109/10837450.2011.604783 ↗
36. Sharma N, Rana S, Shivkumar HG, et al. Solid lipid nanoparticles as a carrier of matformin for transdermal delivery. Int J Drug Del. 2013;5:137.
37. 10.4103/0971-6580.10366710.4103/0971-6580.103667 ↗
38. 10.1016/j.carbpol.2012.04.05010.1016/j.carbpol.2012.04.050 ↗
39. 10.1007/s11095-014-1425-010.1007/s11095-014-1425-0 ↗
40. 10.1038/onc.2014.4210.1038/onc.2014.42 ↗
41. 10.1039/c3ra41346b10.1039/c3ra41346b ↗
42. 10.1371/journal.pone.013334910.1371/journal.pone.0133349 ↗
43. 10.12659/MSM.89871010.12659/MSM.898710 ↗
44. 10.1371/journal.pone.009820710.1371/journal.pone.0098207 ↗
45. 10.1016/j.ijpharm.2016.05.03910.1016/j.ijpharm.2016.05.039 ↗
46. 10.1038/3503771010.1038/35037710 ↗
47. 10.2174/092986732366616042511370510.2174/0929867323666160425113705 ↗
48. 10.1007/s00216-016-0058-z10.1007/s00216-016-0058-z ↗
49. 10.5114/pm.2014.4381710.5114/pm.2014.43817 ↗
50. 10.1007/s13277-013-0757-410.1007/s13277-013-0757-4 ↗